Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020973

« Back to Dashboard
NDA 020973 describes ACIPHEX, which is a drug marketed by Eisai Inc and Fsc Therap and is included in two NDAs. It is available from six suppliers. Additional details are available on the ACIPHEX profile page.

The generic ingredient in ACIPHEX is rabeprazole sodium. There are twenty-nine drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the rabeprazole sodium profile page.

Summary for NDA: 020973

Eisai Inc
rabeprazole sodium
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 020973

Mechanism of ActionProton Pump Inhibitors

Suppliers and Packaging for NDA: 020973

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL 020973 NDA Lake Erie Medical & Surgical Supplies DBA Quality Care Products LLC 49999-447 49999-447-30 30 TABLET, COATED in 1 BOTTLE (49999-447-30)
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL 020973 NDA Physicians Total Care, Inc. 54868-4185 54868-4185-0 30 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (54868-4185-0)

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, DELAYED RELEASE;ORALStrength10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:May 29, 2002TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength20MG
Approval Date:Aug 19, 1999TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 020973

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973-001May 29, 20025,035,899► subscribe
Eisai Inc
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973-002Aug 19, 19995,045,552*PED► subscribe
Eisai Inc
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973-001May 29, 20025,045,552*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.